News & Events

Cyclica is a pharmaceutical big data analysis software and a platform focusing on SAAS services. The company’s products are based on the analysis of the composition, structure, pharmacology and other big data of existing drugs, using artificial intelligence, machine learning and other means to help pharmaceutical companies find other possible uses of existing drugs, and screening drugs for safe use by people through the detection of side effects of drugs.

The Ligand Express platform developed by Cyclica has been verified by a third-party organization and put into use for developing safer and more effective therapies. Whether hypothetical, subclinical, clinical, or FDA certified, Cyclica has analyzed the efficacy of small molecules in these therapies and expressed profound insights, aiming to find more possible uses of drugs and effectively transfer assets from basic research to clinical application.

The platform of Ligand Express is unique and drug centered. At present, the platform features PROBEx (docking of proteins), SWITCHx (prediction of the effects of ligands) and DIVEx (system biology and drug protein interaction), and evaluates and compares their small molecules to predict how they will interact with the human body (such as human proteome). In addition, Cyclica can provide effective information in finding novel, desirable or undesirable goals, which in turn can provide customers with a profile of Poly’s pharmacology. Cyclica has a proprietary database of structurally characterized bacterial and viral proteomes that can identify new therapies for infectious diseases.  

As the CEO of Cyclica, Naheed Kurji is an experienced person specializing in strategic planning, enterprise financing and entrepreneurship, with an MBA degree from Rotman School of Management, University of Toronto. Naheed joined Cyclica in March 2014 as Vice President of Finance, and was appointed Chief Financial Officer in October 2014. As the chief financial officer, he is not only skilled in financial management, financing and investor relations, but also good at strategic planning and business development. In April 2016, the Board of Directors appointed Naheed as President and CEO. He will continue to perform his duties as CFO and focus on the company’s recent development strategy.  

The advantage of Cyclina is that it can support drug development, determine potential non impact targets before clinical trials, save research and development time and costs, and increase resource allocation for other drug development.